News

The global Investigational New Drug CDMO market size is expected to be worth around US$ 13.8 billion by 2030, according to a new report by Vision Research Reports.

The global Investigational New Drug CDMO market size was valued at US$ 9.2 billion in 2020 and is anticipated to grow at a CAGR of 12.9% during forecast period 2021 to 2030.

Get Sample Copy of This Report@ https://www.visionresearchreports.com/report/sample/38506

Report Coverage

Report Scope	Details
Market Size	USD 13.8 billion by 2030
Growth Rate	CAGR of 12.9% From 2021 to 2030
Base Year	2020
Historic Data	2017 to 2020
Forecast Period	2021 to 2030
Segments Covered	Product, Service, End-user
Regional Scope	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned	Lonza; Catalent; Recipharm AB; Siegfried Holding AG; Thermo Fisher Scientific Inc.; Covance Inc.; Charles River Laboratories; Cambrex Corporation; IQVIA Holdings Inc.; Syneous Health

Growth Factors

 The market growth can be attributed to factors such as the increasing outsourcing services by pharmaceutical companies, rising R&D investments, and stringent regulations for conducting clinical studies. The FDA’s role in the development of a novel drug begins when the drug’s sponsor decides to test the new molecule’s diagnostic or therapeutic potential in humans after screening it for pharmacological activity and acute toxicity potential in animals. The molecule then changes its legal position under the Federal Food, Drug, and Cosmetic Act, becoming a new drug subject to the drug regulatory system’s specific requirements.

Report Highlights

The small molecule segment held the largest share of 90.0% in 2020 and is likely to remain dominant over the forecast period. This is largely due to the increasing number of small molecules in development. Small molecules constitute more than 100% of the drugs currently in the market.

The large molecule segment is anticipated to register the fastest CAGR of 10.8% throughout the forecast period. This is largely due to pharmaceutical and biotech companies investing more in the discovery and development of large molecule therapeutic proteins due to their specificity, which allows for the targeting of previously difficult-to-address conditions in disease states, such as oncology, neurology, and metabolic disease.

Key Players

• Covance Inc.
• Charles River Laboratories Inc.
• Cambrex Corporation
• IQVIA Holdings Inc.
• Syneos Health
• Lonza
• Catalent
• Recipharm AB
• Siegfried Holding AG
• Thermo Fisher Scientific Inc.

Market Segmentation

• Product
  • Small Molecule
  • Large Molecule
• Service
  • Contract Development
    • Small Molecule
      • Bioanalysis and DMPK Studies
      • Toxicology Testing
      • Pathology and Safety Pharmacology Studies
      • Drug Substance Synthetic Route Development
      • Drug Substance Process Development
      • Form Selection Crystallization Process Development
      • Scale-up of Drug Substance
      • Pre Formulation
      • Preclinical Formulation Selection
      • First In Man Formulation/ Process Development
      • Analytical Method Development / Validation
      • Release Testing of Drug Substance and Drug Product
      • Work Up Purification Steps
      • Telescoping & Process Refining
      • Initial Optimization
      • Formal Stability of Drug Substance and Drug Product
    • Large Molecule
      • Cell Line Development
      • Process Development
        • Upstream
          • Microbial
          • Mammalian
          • Others
        • Downstream
          • MABs
          • Recombinant Proteins
          • Others
  • Contract Manufacturing
    • Small Molecule
      • Oral Solids
      • Liquid and Semi-solids
      • Injectables
      • Others
    • Large Molecule
      • MABs
      • Recombinant Proteins
      • Others
• End-user
  • Pharmaceutical Companies
  • Biotech Companies
  • Others (Government, Research Institutes, Academic Institutes, etc.)
• Regional
  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Buy This Premium Research Report, click here@ https://www.visionresearchreports.com/report/cart/38506 or call: +1 9197 992 333